Reinhard Depenbusch

833 total citations
15 papers, 341 citations indexed

About

Reinhard Depenbusch is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Reinhard Depenbusch has authored 15 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in Reinhard Depenbusch's work include Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Genomics and Diagnostics (4 papers). Reinhard Depenbusch is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer Genomics and Diagnostics (4 papers). Reinhard Depenbusch collaborates with scholars based in Germany, United States and Belgium. Reinhard Depenbusch's co-authors include Susanna Hegewisch‐Becker, Salah‐Eddin Al‐Batran, Axel Hinke, Christian Lerchenmüller, Georg Dietrich, Thoralf Lange, Ullrich Graeven, Andrea Tannapfel, B. Killing and Dirk Arnold and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Reinhard Depenbusch

12 papers receiving 336 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reinhard Depenbusch Germany	8	311	144	72	68	59	15	341
B. Killing Germany	7	288 0.9×	141 1.0×	51 0.7×	57 0.8×	48 0.8×	9	329
Erica N. Heying United States	6	223 0.7×	86 0.6×	92 1.3×	47 0.7×	48 0.8×	10	285
Nicolas Sommer United States	11	260 0.8×	107 0.7×	107 1.5×	42 0.6×	74 1.3×	27	356
Richard M. Lee‐Ying Canada	10	168 0.5×	125 0.9×	58 0.8×	78 1.1×	71 1.2×	49	299
Stephanie Yasmin Brule Canada	7	307 1.0×	190 1.3×	137 1.9×	77 1.1×	44 0.7×	18	397
Patrick Texereau France	8	221 0.7×	93 0.6×	50 0.7×	41 0.6×	81 1.4×	15	280
Nisha L. Jacobs United States	6	201 0.6×	77 0.5×	68 0.9×	51 0.8×	57 1.0×	10	279
Silvia Ruscelli Italy	8	244 0.8×	67 0.5×	50 0.7×	50 0.7×	56 0.9×	15	304
Soetkin Vlassak Germany	6	239 0.8×	127 0.9×	42 0.6×	84 1.2×	44 0.7×	20	330
Jan-Henrik Terwey United Kingdom	8	264 0.8×	104 0.7×	114 1.6×	51 0.8×	69 1.2×	20	302

Countries citing papers authored by Reinhard Depenbusch

Since Specialization

Citations

This map shows the geographic impact of Reinhard Depenbusch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reinhard Depenbusch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reinhard Depenbusch more than expected).

Fields of papers citing papers by Reinhard Depenbusch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reinhard Depenbusch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reinhard Depenbusch. The network helps show where Reinhard Depenbusch may publish in the future.

Co-authorship network of co-authors of Reinhard Depenbusch

This figure shows the co-authorship network connecting the top 25 collaborators of Reinhard Depenbusch. A scholar is included among the top collaborators of Reinhard Depenbusch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reinhard Depenbusch. Reinhard Depenbusch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Potthoff, Karin, Norbert Marschner, Lothar Müller, et al.. (2025). Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer. 56(1). 141–141.

Link, Hartmut, Gerald Illerhaus, Uwe M. Martens, et al.. (2020). Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Supportive Care in Cancer. 29(5). 2519–2527. 6 indexed citations

Stein, Alexander, Mascha Binder, Eray Goekkurt, et al.. (2020). Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216).. Journal of Clinical Oncology. 38(4_suppl). 96–96. 42 indexed citations

Donskov, Frede, Robert J. Motzer, Éric Voog, et al.. (2019). Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer. 126. 1–10. 18 indexed citations

Hegewisch‐Becker, Susanna, Axel Hinke, Ullrich Graeven, et al.. (2018). Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial. European Journal of Cancer. 101. 105–113. 18 indexed citations

Stein, Alexander, Mascha Binder, Salah‐Eddin Al‐Batran, et al.. (2018). Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).. Journal of Clinical Oncology. 36(15_suppl). 3561–3561. 17 indexed citations

Donskov, Frede, Robert J. Motzer, Éric Voog, et al.. (2017). Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 35(6_suppl). 517–517. 2 indexed citations

Donskov, Frede, Robert J. Motzer, Éric Voog, et al.. (2017). Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 35(15_suppl). 4578–4578.

Welt, Anja, Norbert Marschner, C. Lerchenmueller, et al.. (2016). Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Breast Cancer Research and Treatment. 156(1). 97–107. 15 indexed citations

10.

Quidde, Julia, Susanna Hegewisch‐Becker, Ullrich Graeven, et al.. (2016). Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Annals of Oncology. 27(12). 2203–2209. 18 indexed citations

11.

Quidde, Julia, Ullrich Graeven, C. Lerchenmueller, et al.. (2016). Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial. Annals of Oncology. 27. vi184–vi184.

12.

Hegewisch‐Becker, Susanna, Ullrich Graeven, Christian Lerchenmüller, et al.. (2015). Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. The Lancet Oncology. 16(13). 1355–1369. 176 indexed citations

13.

Hegewisch-Becker, S., Ullrich Graeven, Christian Lerchenmüller, et al.. (2014). Maintenance Strategy with Fluoropyrimidines (Fp) Plus Bevacizumab (Bev), Bev Alone or No Treatment, Following a 24-Week First-Line Induction with Fp, Oxaliplatin (Ox) and Bev for Patients with Metastatic Colorectal Cancer: Mature Data and Subgroup Analysis of the Aio Krk 0207 Phase III Study. Annals of Oncology. 25. iv167–iv167. 7 indexed citations

14.

Quidde, Julia, Dirk Arnold, S. Hegewisch-Becker, et al.. (2014). Quality of Life (Qol) in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Maintenance Therapy After First-Line Inductive Treatment: a Qol Sub-Analysis of the Aio Krk 0207 Phase III Trial. Annals of Oncology. 25. iv177–iv177. 1 indexed citations

15.

Arnold, Dirk, Ullrich Graeven, Christian Lerchenmüller, et al.. (2014). Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).. Journal of Clinical Oncology. 32(15_suppl). 3503–3503. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact